曲美木单抗联合度伐利尤单抗治疗肝细胞癌患者免疫相关因素的多组学分析
研究纳入28例接受度伐利尤单抗、曲美木单抗及局部治疗的肝细胞癌患者,通过全外显子测序、单细胞RNA测序、CODEX、流式细胞术及多重细胞因子分析等多组学方法分析免疫相关因素,中位总生存期为19.2个月,发现应答者肿瘤干扰素反应和抗原呈递增强,非应答者Treg在免疫细胞富集区域增多且Treg-CD8+T细胞相互作用增强。
要点
- 中位总生存期为19.2个月。
- 应答者肿瘤干扰素反应和抗原呈递增强。
- 非应答者Treg在免疫细胞富集区域增多且Treg-CD8+T细胞相互作用增强。
核心结论
- 研究为免疫治疗研究中的免疫相关因素深入分析提供了蓝图,并证明Treg分布在肝细胞癌中的重要性。
研究设计与样本
- 研究治疗了28例肝细胞癌患者,给予度伐利尤单抗、曲美木单抗及局部治疗。
- 对患者血液和肿瘤样本进行高维多组学分析,包括全外显子测序、单细胞RNA测序、CODEX、流式细胞术及多重细胞因子/趋化因子分析。
- 对同基因肝细胞癌小鼠给予抗PD-L1联合抗CTLA4治疗,分析肝脏淋巴细胞、肿瘤浸润淋巴细胞和外周血单个核细胞。
主要发现
- 中位总生存期为19.2个月。
- 肿瘤组织分析显示干扰素反应增强,应答者中效应更强。
- 基因集变异分析提示应答者抗原呈递增强。
- 空间分析显示非应答者肿瘤中Treg数量更多,位于免疫细胞富集的邻近区域,且ICOS和PD-1表达水平更高;这些Treg富集区域中非应答者PD1+CD8+T细胞ICOS表达更低。
- 细胞通讯分析显示非应答者组织中Treg-CD8+T细胞相互作用增强;外周血分析显示应答者经典单核细胞增加,非应答者Treg增加;Treg-CD8+T细胞相互作用在临床前模型中得到证实。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. The combination of tremelimumab and durvalumab is now a standard treatment option for advanced HCC. OBJECTIVE: To study immune responses in HCC patients treated with tremelimumab and durvalumab. DESIGN: We treated 28 HCC patients with durvalumab, tremelimumab and locoregional therapies. We performed a high-dimensional multiomics analysis including whole exome sequencing, single-cell RNA seq, CO-Detection by indEXing, flow cytometry and multiplex cytokine/chemokine analysis of patients' blood and tumour samples and integrated this data to elucidate immune correlatives and response mechanisms. Mice with syngeneic HCC were treated with anti-PD-L1 plus anti-CTLA4 for hepatic lymphocytes, tumour-infiltrating lymphocytes and peripheral blood mononuclear cell analysis. RESULTS: The median overall survival was 19.2 months. Tumour tissue analysis revealed enhanced interferon responses, with stronger effects in responders. Gene set variation analysis indicated enhanced antigen presentation in responders. Spatial analysis revealed that non-responder tumours had higher numbers of Tregs located in neighbourhoods enriched with immune cells and expressed higher levels of ICOS and PD-1. Conversely, non-responder PD1+CD8+T in these Treg-enriched neighbourhoods expressed lower ICOS. Cell-communication analysis demonstrated that Treg-CD8+T interaction was enhanced in non-responder tissue. Peripheral blood analysis showed increased classical monocytes in responders and Tregs in non-responders. Treg-CD8+T interaction was confirmed in preclinical models. Finally, single-patient computational analysis from the all-across analysis was performed on 860 features, which led to the identification of multiomics feature sets including Treg features. CONCLUSION: Our study provides a blueprint for in-depth analysis of immune correlates in immunotherapy studies and demonstrates the importance of Treg distribution in HCC. TRIAL REGISTRATION NUMBERS: NCT02821754 and the EudraCT identifier: 2019-002767-98.
引用
- Myojin Y, Babaei S, Trehan R, et al. Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab. Gut. 2025. PMID: 39965889. doi:10.1136/gutjnl-2024-334026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。